Asthma Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

DelveInsight's "Asthma Pipeline Insight 2026" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Asthma Pipeline Report

* On May 28, 2026- Arrowhead Pharmaceuticals conducted a phase 2A study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
* On May 22, 2026- Eli Lilly and Company initiated a phase 2 study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
* On May 22, 2026- GlaxoSmithKline initiated a phase 2 study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
* On May 20, 2026- Sanofi conducted a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks.
* On May 19, 2026- Shanghai Novamab Biopharmaceuticals Co., Ltd . announced a phase IIb study includes four periods: a screening period of up to 2 weeks to check eligibility, followed by a 2 week run in period during which all participants take a placebo once daily by nebulizer and record symptoms and rescue medication use. Participants are then randomly assigned to one of three groups for the 24 week treatment period: LQ036 12 mg, LQ036 24 mg, or placebo once daily. For the first 12 weeks, the LQ036 groups are compared with the placebo group; after 12 weeks, those originally on placebo are reassigned to either LQ036 12 mg or 24 mg for the remaining 12 weeks. Throughout the study period, all participants continue their usual asthma controller medicines. A 4 week safety follow up visit occurs after the 24 week treatment to monitor for side effects.
* On May 18, 2026- AstraZeneca initiated a Phase III study to assess the efficacy and safety of budesonide and albuterol metered dose inhaler (MDI) versus albuterol sulfate (AS) MDI in symptomatic Chinese adults with asthma. Both treatments will be administered as needed in response to asthma symptoms or prior to exercise. Approximately 790 participants who meet the eligibility criteria will be randomized.
* DelveInsight's Asthma pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Asthma treatment.
* The leading Asthma Companies such as AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
* Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab , and others.

Stay informed about the cutting-edge advancements in Asthma treatments @ Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Asthma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Asthma Pipeline Report also highlights the unmet needs with respect to the Asthma.

Asthma Overview

Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide and presents substantial challenges in both diagnosis and management. This respiratory condition is characterized by inflammation of the airways, causing intermittent airflow obstruction and bronchial hyperresponsiveness. The prevalence and severity of asthma are determined by a complex interplay between genetic and environmental factors. Asthma symptoms vary between individuals and can sometimes worsen into episodes known as asthma attacks, often occurring at night or during physical activity. Common signs include a persistent cough (especially at night), wheezing during breathing, shortness of breath even at rest, and a feeling of chest tightness that makes deep breathing difficult. Symptoms may intensify with triggers such as colds, weather changes, dust, smoke, pollen, or strong odors. Since similar symptoms can arise from other conditions, it is important to consult a healthcare provider for proper evaluation and diagnosis.

Asthma Emerging Drugs Profile

* GB-0895: Generate:Biomedicines

GB-0895 is an investigational antibody that binds and neutralizes thymic stromal lymphopoietin (TSLP) to help reduce downstream inflammatory signaling in severe asthma. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Asthma.

* AZD-4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. In a preclinical ovalbumin-challenge rat model of allergic asthma, lung and systemic delivered AZD4604 showed reduction of pSTAT3 and pSTAT5, indicating target engagement in the lung. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

* ENV-294: Enveda

ENV-294 is a novel, first-in-class, small molecule discovered using Enveda's proprietary platform for the treatment of multiple inflammatory conditions. It targets a novel non-kinase inflammatory pathway distinct from current advanced therapies like JAK-STAT or cytokine signaling, aiming to deliver an oral agent with high efficacy and favorable safety. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

* CDX-622: Celldex Therapeutics

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. SCF activation of the KIT receptor is required for mast cell survival and plays a key role in their activation, maturation and tissue recruitment. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

* SM17: SinoMab BioScience Ltd

SM17 is a novel, first-in-class humanized IgG4- monoclonal anbody designed to modulate Type II inflammatory responses by targeng the receptor of interleukin 25 (IL-25), an "alarmin" molecule central to Type 2 immunity. By binding to the IL-25 receptor (IL-17RB) on Type 2 innate lymphoid cells (ILC2s) and Th2 cells, SM17 blocks IL-25-induced signaling cascades and suppresses downstream cytokines including IL-4, IL-5, and IL-13. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Asthma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
* Asthma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

Asthma Companies

AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Asthma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Asthma treatment by visiting our website @ Asthma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Asthma Pipeline Report

* Coverage- Global
* Asthma Companies- AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
* Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab , and others.
* Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Introduction

2. Executive Summary

3. Asthma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Asthma - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Asthma - Key Companies

13. Asthma - Key Products

14. Asthma - Unmet Needs

15. Asthma - Market Drivers and Barriers

16. Asthma - Future Perspectives and Conclusion

17. Asthma - Analyst Views

18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=asthma-pipeline-shows-strong-momentum-as-80-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/asthma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/asthma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.